bims-migras 2026-08-02 papers

Issue of 2026–08–02
two papers selected by
Cliff Dominy

Am J Reprod Immunol. 2026 Aug;96(2): e70272

EVT-Derived Migrasomes Provide Mechanistic Insights Into Antiphospholipid Syndrome-Associated Recurrent Miscarriage.

Di Wang, Yu Xie, Hongyuan Zhang, Tingting Dong, Xiaoyu Liu, Yilei Li, Yan Zhang, Xietong Wang, Qian Zhou.

OBJECTIVE: Recurrent miscarriage (RM) is a complex pregnancy-related disorder closely associated with impaired extravillous trophoblast (EVT). Antiphospholipid antibody syndrome (APS) is an autoimmune condition that contributes to adverse pregnancy outcomes, including RM. However, the mechanism by which APS induces RM remains largely unclear. Migrasomes, a newly identified type of extracellular vesicle generated during cell migration, may regulate cellular functions through the transfer of microRNAs (miRNAs). Increasing evidence has suggested that migrasomes play important roles in the female reproductive system, particularly in pregnancy-related disorders such as RM. This study aimed to explore the potential role and underlying mechanism of EVT-derived migrasomes in the pathogenesis of RM associated with APS.
METHODS: First, EVT-derived migrasomes (EVTDMs) were isolated from an in vitro RM/APS model established in HTR-8/SVneo cells. Differentially expressed miRNAs in EVTDMs were identified by small RNA sequencing, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The predicted target gene of hsa-miR-206 was further validated using a dual-luciferase reporter assay.
RESULTS: The results showed that migrasome markers were readily detected in EVTDMs derived from HTR-8/SVneo cells. An in vitro RM/APS model was established by co-incubation with anti-β2-glycoprotein I antibody (anti-β2-GPI Ab). Migrasome-like vesicles were identified by confocal microscopy and transmission electron microscopy. MiRNA profiling revealed that hsa-miR-206 was significantly upregulated in EVTDMs from the RM/APS group. Based on bioinformatic prediction and dual-luciferase reporter assays, IKBKB was identified as a direct binding target of hsa-miR-206.
CONCLUSION: In conclusion, HTR-8/SVneo cells were capable of generating migrasome-like vesicles, and anti-β2-GPI Ab treatment altered the miRNA cargo of EVTDMs. Among the differentially expressed miRNAs, hsa-miR-206 was markedly upregulated and was validated to bind directly to the 3'UTR of IKBKB, suggesting a potential role in posttranscriptional regulation. However, the downstream functional consequences of this interaction remain to be further elucidated.

Keywords: antiphospholipid syndrome‐associated recurrent miscarriage (RM/APS); extravillous trophoblast‐derived migrasomes (EVTDMs); miRNAs

DOI: https://doi.org/10.1111/aji.70272

Cancer Res Treat. 2026 Jul 15.

A Prognostic Risk Model for Breast Cancer Integrating Migrasome and Tumor Microenvironment Features to Predict Immunological Characteristics.

Jingbo Du, Lin Zhu.

Purpose: Breast cancer (BRCA) is a heterogeneous disease with a complex etiology. The prognostic value of genes related to migrasomes and the tumor microenvironment (MTMERGs) in BRCA is unclear.
Materials and Methods: A prognostic risk model was constructed using six core signature genes identified from MTMERGs via differential expression analysis and Cox regression. Its reliability was validated in an independent cohort using Kaplan-Meier and time-dependent ROC curves. A nomogram was developed and assessed via Decision Curve Analysis (DCA). Biological functions and immune infiltration were evaluated with GSEA, CIBERSORT, and ssGSEA. Immunotherapy sensitivity was predicted using TIDE/IPS scores and the IMvigor210 cohort. Tumor Mutation Burden (TMB) analysis and the pRRophetic algorithm were used for further clinical correlation and drug sensitivity prediction.
Results: The six-MTMERG model effectively stratified patients into high- and low-risk groups with distinct survival outcomes. The high-risk group was associated with a predicted immunosuppressive microenvironment (estimated enrichment of M0/M2 macrophages), higher TMB, and poorer prognosis. In contrast, the low-risk group was estimated to possess an immunologically active profile and showed a better predicted response to immune checkpoint inhibitors. Predicted differential sensitivities to conventional chemotherapy were also computationally evaluated between the subgroups.
Conclusion: We developed a computationally derived and externally validated prognostic model for BRCA based on migrasome and tumor microenvironment features. It successfully stratifies patients into groups with divergent clinical outcomes, immune profiles, and therapeutic responses, providing insights into BRCA heterogeneity and prognosis. Further prospective and experimental validation is warranted before clinical application.

Keywords: Breast neoplasms; Immunological characteristics; Migrasome and tumor microenvironment-related genes; Prognostic

DOI: https://doi.org/10.4143/crt.2025.1417